Dominari Holdings Inc. 10-Q

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds None. Item 6. Exhibits 10.1* Master License Agreement, dated as of April 13, 2020, by and between AIkido Pharma, Inc. and the University of Maryland, Baltimore (incorporated herein by reference to Form S-3/A filed on June 12, 2020) 31.1 Certification of Principal Executive Officer and Principal Financial Officer of AIkido Pharma Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1 Certification of Principal Executive Officer and Principal Financial Officer of AIkido Pharma Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS XBRL Instance Document. 101.SCH XBRL Taxonomy Extension Schema Document 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF XBRL Taxonomy Extension Definition Linkbase Document 101.LAB XBRL Taxonomy Extension Label Linkbase Document 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document * Portions of this document have been redacted. 36 Signatures Pursuant to the requirements of the Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Aikido Pharma Inc. (Registrant) Date: August 6, 2020 By: /s/ Anthony Hayes Anthony Hayes Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer) 37